Drug intelligence / Profile preview

TPF-D

Development stage: Preclinical
Lead developer: The Affiliated Hospital of Xuzhou Medical University
Modality: Small Molecules
Administration: Enteral

Overview

TPF-D is an enteral nutrition emulsion developed by the Emergency Department of Affiliated Hospital of Xuzhou Medical College and Affiliated Hospital of Xuzhou Medical College. It is currently being investigated for its effects on blood glucose levels and prognosis in patients with stress hyperglycemia. Additionally, it is being studied for its effectiveness in patients with chronic wounds and diabetes. A related formulation, TPF-DM, is described as a high-fat, high-energy, low-carbohydrate enteral complete nutrition preparation, suitable for cancer patients, containing ω-3 fatty acids, vitamins A, C, E, and dietary fiber to support immune function, enhance resistance, and maintain gastrointestinal health.

Brand names: Ruidai
Other names: enteral nutrition emulsion (TPF-D)

Beyond the preview

Go deeper on TPF-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPF-D.

Explore the full profile